Global Auto-Injectors Market Size

Auto-injectors Market Analysis

The Global Auto-Injectors Market size is estimated at USD 10.84 billion in 2024, and is expected to reach USD 22.83 billion by 2029, growing at a CAGR of 16.05% during the forecast period (2024-2029).

The COVID-19 pandemic has exerted favorable and unfavorable impacts on the healthcare industry. This is likely because most autoinjector products are administered at home by the patient. Patients who use autoinjectors don't have to leave their homes to receive care, which is advantageous when trying to maintain social distance during the pandemic. The rising COVID-19 patient population is putting a strain on hospital systems and the availability of medical supplies for each patient and the hospital. Due to increased demand for medical supplies such as injections, pre-filled syringes, and other items, manufacturers have increased their production capacity to meet the demand-supply balance. Covid-19 has had a significant impact on the market for auto-injectors.

The factors that are driving the market growth include increasing demand for the convenience of patients, rising incidence of chronic and lifestyle diseases, and technological advancements. According to World Health Organization Reports, in 2021, over 16 billion injections were given annually worldwide. Thus, the rising number of injections annually drives the demand for auto-injectors, thereby boosting the market.

According to the World Health Organization (WHO), the prevalence of chronic diseases is expected to rise by 57% by 2020, and 60% of this burden is likely to occur in emerging markets. Chronic diseases (CD) of various types are found to be the leading causes of disability and morbidity around the world. According to the Globocan 2020 report, 19,292,789 new cancer cases were diagnosed worldwide, with 9,958,133 cancer-related deaths. Furthermore, according to the International Diabetes Federation Report in December 2021, Diabetes affects approximately 537 million adults aged 20 to 79. By 2030, the total number of diabetics is expected to reach 643 million; by 2045, it will reach 783 million. Three out of every four adults with diabetes live in a low- or middle-income country. Moreover, according to the World Health Organization 2020 report, in 2020, it was estimated that around 10 million people suffered from tuberculosis globally. This includes 5.6 million men, 3.3 million women, and 1.1 million children. Tuberculosis affects people of all ages and from all countries. The 30 most affected countries by tuberculosis accounted for 86% of new cases in 2020. India leads the pack with two-thirds of the total, followed by China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa. Thus, the increase in the number of chronic diseases boosts the market growth over the forecast period.

The use of an auto-injector has brought many benefits for both the patient and healthcare professional. It has simplified self-administration, reduced anxiety, improved safety, and improved compliance. Furthermore, with the tremendous opportunity in the market, many market players are adopting various strategies, such as collaborations, acquisitions, new product launches, and expansions. For instance, in September 2021, Owen Mumford Pharmaceutical Services, a division of Owen Mumford Ltd, launched its new Aidaptus auto-injector platform following the successful completion of development. Additionally, in July 2021, Otsuka Pharmaceutical Co., Ltd. (Otsuka) applied to Japan's Ministry of Health, Labour, and Welfare for an additional dosage form, auto-injector, for AJOVY Subcutaneous Injection 225 mg (a generic name is fremanezumab).

Thus, the abovementioned factors are expected to drive market growth over the forecast period. However, preference for alternative dosage delivery modes and regulatory hurdles may hinder the growth of the market.